Sign up Australia
Proactive Investors - Run By Investors For Investors

Alliance Pharma brings on board its third international product with US$17.5mln Vamousse deal

It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
m&a icon of bug fish swallowing big fish
Deal done - the company has completed more than 30 acquisitions

Alliance Pharma PLC (LON:APH) shares rose 5% after it said it was acquiring a pesticide-free head lice product line for up to US$17.5mln – giving the growing healthcare company a third international brand.

It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech PLC, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets.

READ: Alliance Pharma buys rights to anaesthetic gel product, Ametop from Smith & Nephew for US$7.5mln

The earnings enhancing deal should be completed by the end of the year.

Using existing infrastructure

“Vamousse will leverage our current infrastructure as it fits well into our growing UK consumer business, whilst expanding our footprint into the US,” said Alliance chief executive John Dawson.

“The brand will also benefit from added distribution both through our EU affiliates and through our international partner network operating in over 90 territories worldwide."

READ: Cash generative Alliance Pharma poised for further growth

In the last full financial year, Vamousse’s mousses and shampoos generated sales of US$6.6mln and a gross profit of US$4.6mln. In the latest six months, revenues were US$3.3mln and gross profit US$2.3mln.

US focused 

A total of 83% of the turnover came from the US, with the remainder generated in the UK.

"We are delighted to acquire the innovative consumer healthcare brand Vamousse, which will become our third major international growth brand,” said Alliance CEO Dawson.

“The acquisition will be immediately earnings enhancing and expected to be accretive to our return on invested capital from the second year.”

The sale of Vamousse should provide a significant boost to shares in Tyratech as the initial consideration being handed over by Alliance is US$3mln more than the AIM firm’s current market capitalisation.

Tyratech has said it will use US$8.5mln of the proceeds to buy back its stock for 3 pence a share – which is more than double Friday’s close.

Well-judged acquisitions 

The company has grown via a series of well-judged acquisitions (35 now in 19 years) and Alliance owns around 90 pharmaceutical and healthcare products and sells into over 100 countries.

In that portfolio, it has what it calls ‘local hero’ lines, which sell well in a particular territory or country.

The crown jewels are its ‘global stars’, which are managed and marketed centrally and, as the name suggests, are sold internationally.

They are Kelo-Cote, a scar reduction spray and gel, and MacuShield, for an eye condition called age-related macular degeneration.

The former saw its sales increase 52% in the first half to US$8.4mln, while the latter’s advanced 67% to US$4.6mln. In other words, they showed their ‘star’ quality.

Third international brand

Vamousse adds a third leg to the firm’s global aspirations.

Alliance shares rose 3.22p to 61.97p following the unveiling of the deal. Numis thinks the stock is worth 71p.

The City broker has raised its earnings per share forecasts by 3% and 4% respectively for next year and the year after to factor in the bottom line impact of Vamousse and Ametop, an anaesthetic gel it acquired last week (Dec 1) for US$7.5mln.

“We view both acquisitions as sensible value-enhancing bolt-ons with the potential to leverage Alliance's improving international reach and scale,” said analyst Sally Taylor.

View full APH profile View Profile

Alliance Pharma plc Timeline

Related Articles

1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use